ArticlePLoS medicine2026
Subsequent primary cancer incidence among cancer survivors in the United States, 1975-2019: An age-period-cohort analysis.
Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe growing population of cancer survivors faces elevated risks of subsequent primary cancers (SPCs), yet temporal patterns in SPC incidence remain poorly understood. This study aims to characterize age-, period-, and cohort-specific patterns in SPC incidence among US cancer survivors using population-based data. METHODS AND
findingsWe conducted a retrospective cohort study using Surveillance, Epidemiology, and End Results (SEER) 8 registries, identifying 3.36 million individuals diagnosed with a first primary cancer between 1975 and 2019. Survivors were followed through 2022 to estimate the incidence of SPCs. We used age-period-cohort analysis to estimate longitudinal age curves, cohort and period rate ratios, and annual percent changes in SPC incidence. Analyses were stratified by sex and the five most common index cancer sites. During 29.5 million person‑years of follow‑up, 510,340 SPCs were observed. SPC incidence increased with age at index cancer diagnosis, rising among females from 915 per 100,000 person‑years at ages 35-39 years to 1,980 per 100,000 at ages 75-79 years, and among males from 1,228 per 100,000 to 2,945 per 100,000 across the same age groups, demonstrating steeper rises in men. Cohort-specific SPC risk peaked in the 1935-1945 birth cohorts and declined in later cohorts, except among female survivors of lung cancer and male survivors of bladder cancer, where risks continued to rise. Period patterns showed overall declines in SPC incidence, particularly among survivors diagnosed at a younger age, but increasing risks among survivors diagnosed at an older age and survivors of specific index cancer sites. Notably, SPC incidence rose by 60% among female lung cancer survivors between 1975-1979 and 2015-2019 (incidence rate ratio = 1.60, 95% CI [1.22, 2.09]; p < 0.001). Main limitations include the descriptive nature of age-period-cohort analyses and the absence of treatment, genetic, and lifestyle data in SEER.
conclusionsSPC risk is shaped by complex, site- and sex-specific temporal patterns. These findings underscore the need for tailored survivorship care strategies that incorporate age, cohort, and index cancer site to mitigate future SPC burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.